This presentation contains "forward-looking" statements which are statements relating to future events. These statements include those relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These uncertainties may cause our actual future results to be materially different than those expressed in our forward looking statements. A detailed description of these risk factors can be found under the caption “Risk Factors” in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this presentation.

In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are available on the “Financial Information” section of our website at www.perkinelmer.com.
Innovating for a healthier world

Leading global technology company with differentiated capabilities in detection, imaging, assay development, and service

2018 versus 2014

- Revenue: $2.8 Billion (up 35%)
- EPS: $3.60 per share (up 46%)
- Market Cap: $8.3 Billion (up 80%)

- Revenue: $2.0 Billion
- EPS: $2.47 per share
- Market Cap: $4.6 Billion
PKI has undergone significant changes since 2014

- Human Health 55%
- Environmental Health 45%

- Discovery & Analytical Solutions 60%
- Diagnostics 40%

15 Transactions

~$220M Divested

~$550M Acquired
PKI has undergone significant changes since 2014

Changes focused on …
• Attractive End Markets
• Expanding Capabilities
• Geographic Reach
• Improved Product Mix

Resulting in:
✓ Higher Growth
✓ Increased Resiliency
✓ Greater Profitability

15 Transactions
~$220M Divested
~$550M Acquired
INCREASED FOCUS ON ATTRACTIVE END MARKETS

**Weighted Market Growth**
- **2014**: 2-3%
- **2018F**: 4-6%

**Organic Revenue Growth**
- **‘15**: 4%
- **‘16**: 2%
- **‘17**: 4%
- **‘18F**: 7%

**Addressable Market**
- **‘15**: ~$16B
- **‘18F**: ~$45B
# Significantly Expanded Capabilities

<table>
<thead>
<tr>
<th>Acquisitions</th>
<th>Technical Capabilities</th>
<th>End Markets / Commercial</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EUROIMMUN</strong></td>
<td>• Detection&lt;br&gt;• Automation&lt;br&gt;• Assay Development&lt;br&gt;• Antibodies/Antigens</td>
<td><strong>Diagnostics</strong>&lt;br&gt;<strong>Global</strong></td>
</tr>
<tr>
<td><strong>Tulip Group</strong></td>
<td>• ImmunoDx Reagents&lt;br&gt;• Lateral Flow</td>
<td><strong>Diagnostics</strong>&lt;br&gt;<strong>Emerging Markets</strong></td>
</tr>
<tr>
<td><strong>Bio Scientific</strong>&lt;br&gt;a PerkinElmer company</td>
<td>• Rapid Detection Assays&lt;br&gt;• NGS Reagents&lt;br&gt;• Mass Spectrometry&lt;br&gt;• Single Cell</td>
<td><strong>Diagnostics</strong>&lt;br&gt;<strong>Food</strong></td>
</tr>
<tr>
<td><strong>RHS IONICS</strong>&lt;br&gt;Mass Spectrometry</td>
<td>• Analytical Technologies&lt;br&gt;• Informatics</td>
<td><strong>Food</strong>&lt;br&gt;<strong>Global</strong></td>
</tr>
<tr>
<td><strong>Perten</strong></td>
<td>• Analytical Technologies&lt;br&gt;• Sample Handling</td>
<td><strong>Life Sciences</strong>&lt;br&gt;<strong>Environmental &amp; Industrial</strong></td>
</tr>
</tbody>
</table>
## Significantly Expanded Capabilities in Key Markets

### Diagnostics

<table>
<thead>
<tr>
<th>Leading Positions</th>
<th>Revenue</th>
<th>Headcount</th>
<th>Technologies</th>
</tr>
</thead>
<tbody>
<tr>
<td>✓ Newborn Screening</td>
<td>✓ Reproductive Health</td>
<td>✓ Emerging Infectious Diseases</td>
<td>✓ Autoimmune Disease</td>
</tr>
<tr>
<td>✓ Emerging Markets: $450 million</td>
<td>✓ Emerging Markets: $450 million</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✓ R&amp;D: 250</td>
<td>✓ R&amp;D: 1,000</td>
<td></td>
<td></td>
</tr>
<tr>
<td>✓ Commercial: 300</td>
<td>✓ Commercial: 2,400</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2014</th>
<th>2018F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total: $450 million</td>
<td>Total: $1.1 billion</td>
</tr>
<tr>
<td>Emerging Markets: $50 million</td>
<td>Emerging Markets: $450 million</td>
</tr>
<tr>
<td>R&amp;D: 250</td>
<td>R&amp;D: 1,000</td>
</tr>
<tr>
<td>Commercial: 300</td>
<td>Commercial: 2,400</td>
</tr>
</tbody>
</table>

1. Immuno & Clinical Chemistry
2. Detection & Automation
3. PCR
4. Mass Spec
5. NGS Workflow
6. Single Cell Genomics
## Significantly Expanded Capabilities in Key Markets

### Life Sciences

<table>
<thead>
<tr>
<th>Focus</th>
<th>2014</th>
<th>2018F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic Research</td>
<td></td>
<td>Drug Discovery</td>
</tr>
<tr>
<td>Imaging</td>
<td>Commoditized/Aging</td>
<td>5 New Platforms</td>
</tr>
<tr>
<td>Reagents</td>
<td>Non-Rad &lt; 40%</td>
<td>Non-Rad &gt; 70%</td>
</tr>
<tr>
<td>Services</td>
<td>Asset Management</td>
<td>High Value Services</td>
</tr>
<tr>
<td>Informatics</td>
<td>Standalone/Enterprise</td>
<td>Integrated/Cloud Based</td>
</tr>
</tbody>
</table>
SIGNIFICANTLY EXPANDED CAPABILITIES IN KEY MARKETS

Food

<table>
<thead>
<tr>
<th></th>
<th>2014</th>
<th>2018F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Business</td>
<td>Episodic Sales</td>
<td>Leader in Food Safety &amp; Quality</td>
</tr>
<tr>
<td>Revenue</td>
<td>&lt; $100 million</td>
<td>$200+ million</td>
</tr>
<tr>
<td>Products</td>
<td>Primarily Analytical</td>
<td>Cross-PKI Offerings</td>
</tr>
<tr>
<td>R&amp;D / Commercial</td>
<td>Not Separate</td>
<td>Focused Market Specialists</td>
</tr>
</tbody>
</table>
INCREASED FOCUS ONEmerging MARKETS AND Consumables

Geographic Reach

Emerging Markets
- 2014: 28%
- 2018F: 40%
- Increase: 12%

Developed Markets
- 2014: 72%
- 2018F: 60%

Product Mix

Consumables, Services, & Software
- 2014: 55%
- 2018F: 68%
- Increase: 13%

Instruments
- 2014: 45%
- 2018F: 32%
ATTRACTION AND GROWING MARKETS...

**Life Sciences (35%)**
- Emphasis on R&D productivity
- Focus on translation research and data analytics

**Diagnostics (40%)**
- Molecular Dx penetration
- Decentralization of health care

**Food (8%)**
- Increasing testing and safety regulations
- Growing global demand

**Environmental & Industrial (17%)**
- Sustainability of water resources
- Scarcity of environmental resources
… AND IS POSITIONED TO WIN ACROSS ALL MARKETS

**Life Sciences**
- Total workflow solution –optimized for wide range of disease models
- World leader in imaging and software for powerful quantitative analysis at the single cell level

**Diagnostics**
- #1 provider of newborn screening tests worldwide
- #1 platform agnostic automation provider to sequencing labs
- #1 global player in autoimmune in-vitro diagnostics

**Food**
- Leader in quality testing of Grains
- Strong portfolio for Dairy testing
- Emphasis on QA/QC and process control

**Environmental & Industrial**
- Best in class spectroscopy portfolio
- Market leader in atomic absorption with ~30% market share
Current portfolio ... several opportunities to accelerate growth

Weighted Market Growth

- Improved Portfolio: 2.5%
- Growth Accelerators: 2-4%
- Current portfolio: 5.0%
- 2014: 2.5%
- 2018F: 5.0%
- 2020: 7-9%

Growth Accelerators
- Reproductive Health
- Applied Genomics
- ImmunoDx
- Services
- Food & Cannabis
- Market Synergies
Growth Accelerators

POSITIONED FOR FASTER GROWTH THROUGH FOCUSED INVESTMENTS

Reproductive Health
Applied Genomics
ImmunoDx
Services
Food & Cannabis
Market Synergies

Reproductive Health
Of the 140 million babies born every year, only one-third are screened for disorders

A global average of 8 disorders are screened per baby but testing is expanding.

Birth-related healthcare spend has tripled due to increased testing.

Technological advances are reducing the cost and increasing availability and access to better care.
GLOBAL LEADER IN COMPREHENSIVE AND INTEGRATED WORKFLOWS FOR REPRODUCTIVE HEALTH

Leader in biochemical prenatal screening
PKI conducts 45% of the 21M biochemical screens

#1 in Newborn Screening worldwide
PKI screens 35 million newborns every year

Leader in rare disease testing
Whole genome sequencing on cord blood & genomics testing of newborn rare diseases
VANADIS™ NIPT
AUTOMATED WORKFLOW FOR HIGH-PRECISION SCREENING

✔ Easy-to-use technology
   Fully-automated, sample-to-solution, walk-away technology with remote operational capability

✔ Highly precise, fully optimized results
   Greater than 99% detection of T21 with no call / test failure rate of less than 0.5%

✔ Cost-effective solutions
   Non-sequencing, non-PCR solutions with little training time required for functional use
200M Pregnancies

27M Screened**

Biochem (21M)  NIPT (6M)

PKI - 10M (~40%)

PKI - 35M (70%+)

140M Births

45M Screened

Biochem (21M)  NIPT (6M)

Market Potential*

$B’s

1234

* Assumes $100/test

**Does not include Maternal screens

vanadis diagnostics
a PerkinElmer company

NIPT (6M)

= 1 million

= PKI Customer

208 M Pregnancies

140 M Births

* Assumes $100/test

**Does not include Maternal screens
IVF TESTING
- RHS – Genomic solutions

PRENATAL-Fetal
- Biochemical screening
- Vanadis – genetic screening

PRENATAL-Maternal
- Pre-eclampsia screening

CORD BANKING
- ViaCord – cord & tissue banking

NEWBORN
- Newborn screening
- Genetic Testing Services

200M Pregnancies
140M Births
POSITIONED FOR FASTER GROWTH THROUGH FOCUSED INVESTMENTS

PerkinElmer®
For the Better

Growth Accelerators

Reproductive Health
Applied Genomics
ImmuNoDx
Services
Food & Cannabis
Market Synergies

Food & Cannabis
EMERGING MIDDLE CLASS DEMANDS SAFER & HEALTHIER FOOD TO GROWTH IN $35 BILLION MARKET

The last 5 years have seen a steep rise in food safety recalls (21% CAGR), prompting increased safety regulations.

UN expects global food demand to increase 60% to 98% by 2050, requiring innovative production solutions to meet demand.

The competitive landscape is highly fragmented with the top 15-20 players sharing only ~30% of the testing market.
The legalization of cannabis continues to push the frontiers of plant science

Legalization of cannabis worldwide is driving the high-growth market of 60% CAGR.

Demand for credible, science-backed “safe cannabis products” is increasing.

The need for testing expertise is growing due to strict QA / QC of cannabis products.
Serving as your complete food, cannabis, and hemp science partner

Intimate customer relationships
Established relationships with top customers & governmental regulatory departments, and extensive experience in food & cannabis testing

Compelling portfolio to meet customer needs
Bespoke cannabis solutions and complete offerings for ensuring quality of food items across value chains

Strong foundation in food safety
Ability to meet food safety testing needs with competencies raging from immunoassay to genomics
Qsight 420 LC/MS/MS: The Cannabis Lab Solution

- **Full safety characterization**
  One instrument quantifies all pesticides (eg. 95 Canadian or 65 California Pesticides)

- **Turnkey Standard Operating Procedure**
  Cannabis specific configuration & application centric SOP allows seamless implementation

- **A full solution from a trusted provider**
  Product portfolio enables testing on heavy metals, residual solvents, terpenes, and potency
Reproductive Health  
Applied Genomics  
ImmunoDx

Services  
Food & Cannabis  
Market Synergies

POSITIONED FOR FASTER GROWTH THROUGH FOCUSED INVESTMENTS
Increasing Convergence across Diagnostics, Life Sciences, & Food

Digital marketing & augmentations of traditional channels

Customer Experience
Seamless, multichannel experiences with real-time service provisions

Product & Service Innovation
Similar application & product features

Digital Capabilities

Technology Platforms
Imaging, detection, liquid handling, assay development, and informatics

Informatics
Analytics increasingly critical

Dx Customers
Manufacturing & Logistics Operations

R&D
- Antibodies
- Liquid Handling
- Assay Development
- Detection

Product Mgmt.
- Reproductive Health
- ImmunoDx
- Genomics
- Services

DAS Customers
Commercial

R&D
- Imaging
- Detection
- Assay Development
- Informatics

Product Mgmt.
- Pharma
- Food
- Env. / Applied
- Services

Supporting Functions

INCREASING CONVERGENCE ACROSS DIAGNOSTICS, LIFE SCIENCES, & FOOD

Seamless, multichannel experiences with real-time service provisions

Digital marketing & augmentations of traditional channels

Customer Experience

Product & Service Innovation

Informatics

Technology Platforms

Imaging, detection, liquid handling, assay development, and informatics

Analytics increasingly critical

Aligning our organization to deliver:

- Growth
- Innovation
- Simplification

Dx Customers

Dx Commercial

DAS Commercial

Manufacturing & Logistics Operations

R&D
- Imaging
- Detection
- Liquid Handling

- Assay Development
- Informatics

Product Management

Supporting Functions
CONTINUED OPERATING MARGIN EXPANSION … DRIVEN BY

Factory Productivity (1/3)

2019: Design for Manufacturing / Integrated Supply Chain
2018: Platform & Component Standardization
2017: Lean Production / Sourcing

Supply Base Commonality

Growth & Mix (1/3)

2018F 2020F

Leverage (1/3)

2018F 2020F
2020 Financial Outlook

Revenue
High single digit revenue CAGR

Portfolio
~45% emerging markets and >70% consumables, service & software

EPS
Mid-teens EPS CAGR

Margin
Adjusted operating margin of 22%
TRACK RECORD OF STRONG PERFORMANCE

Shareholder Returns

- Healthcare Index (XLV)
- S&P 500 (SPX)
- PKI

<table>
<thead>
<tr>
<th>Time</th>
<th>Healthcare Index (XLV)</th>
<th>S&amp;P 500 (SPX)</th>
<th>PKI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Year</td>
<td>6%</td>
<td>-4%</td>
<td>8%</td>
</tr>
<tr>
<td>3 Year</td>
<td>26%</td>
<td>30%</td>
<td>49%</td>
</tr>
<tr>
<td>5 Year</td>
<td>68%</td>
<td>50%</td>
<td>95%</td>
</tr>
<tr>
<td>10 Year</td>
<td>288%</td>
<td>243%</td>
<td>516%</td>
</tr>
</tbody>
</table>

Source: Fidelity Stock Quote & Research
PerkinElmer: Essential for Understanding Life

Create Healthier Families
- Non-invasive Prenatal Testing
- Newborn Screening
- Genetic Testing

Improve Quality of Life
- Food Testing
- Water Safety
- Cleaner Environment

Sustain Health and Longevity
- Euroimmun Platform
- Applied Genomics
- Drug Development
Differentiated capabilities
Serving attractive markets
Delivering strong results
Making a global impact